Skip to main content
SpringerLink
Log in

Neuroendocrine Tumors

  • Chapter
Nuclear Oncology

Abstract

Neuroendocrine tumors encompass a wide range of uncommon neoplasms derived from diverse tissues and from cells that are believed to have a common embryological origin from neural crest and closely related tissues [1–4] (Table 1.1). Among the features of these tissues, cells, and tumors are: the capacity to synthesize peptide neurotransmitter/hormones; biogenic amine precursor uptake and decarboxylation (hence the terms APUD and APUDomas); intracytoplasmic storage granules on electron microscopy and formalin induced fluorescence (FIF) [5–7]. Many also express cell surface receptors for somatostatin. Nuclear medicine has exploited biogenic amine uptake and cytoplasmic granule storage mechanisms for metaiodobenzylguanidine (MIBG) and related radiopharmaceuticals, and somatostatin receptors for radiolabeled somato-statin-analogs (e.g., [111In-DTPA]octreotide), for imaging tumors of neuroendocrine origin.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Bravo EL, Gifford RW (1984) Pheochromocytoma: diagnosis, localization and management. N Engl J Med 311:1298–1303

    Article  PubMed  CAS  Google Scholar 

  2. Coupland RE (1965) The natural history of the chromaffin cell. Longmans Green and Co, London

    Google Scholar 

  3. Shapiro B, Fig LM (1989) Management of pheochromocytoma. Endocrinol Metab Clin North Am 18:443–481

    PubMed  CAS  Google Scholar 

  4. Sheps SG, Jian N-S, Klee GG, vanHeerden JA (1990) Recent developments in the diagnosis and treatment of pheochromocytoma. Mayo Clin Proc 65:88–95

    PubMed  CAS  Google Scholar 

  5. Gould VE, Memoli V, Chejfec G, Johannessen JV (1979) The APUD cell system and its neoplasms: observations on the significance and limitations of the concept. Surg Clin North Am 59:93–107

    CAS  Google Scholar 

  6. Pearse AGE, Takor T (1976) Neuroendocrine embryology and the APUD concept. Clin Endocrinol 5 [Suppl]:229s-244s

    Article  Google Scholar 

  7. Von Moll L, McEwan AJ, Shapiro B, Sisson JC, Gross MD, Lloyd R, Beals E, Beierwaltes WH, Thompson NW (1987) Iodine-131 MIBG scintigraphy of neuroendocrine tumors other than pheochromocytoma and neuroblastoma. J Nucl Med 28:979–988

    Google Scholar 

  8. Shapiro B, Gross MD, Sisson JC (1995) Neural crest structures. In: Wagner HN, Szabo Z, Buchanan JW (eds) Principles of nuclear medicine, 2nd edn. Saunders, Philadelphia, pp 665–679

    Google Scholar 

  9. McEwan AJ, Shapiro B, Sisson JC, Beierwaltes WH, Ackery DM (1985) Radio-iodobenzylguanidine from the scintigraphic location and therapy of adrenergic tumors. Semin Nucl Med 15:132–153

    CAS  Google Scholar 

  10. Morales JO, Beierwaltes WH, Counsell RE, Meier DE (1967) The concentration of radio-activity from labeled epinephrine and its precursors in the dog adrenal medulla. J Nucl Med 8:800–809

    PubMed  CAS  Google Scholar 

  11. Wieland DM, Swanson DP, Brown LE, Beierwaltes WH (1979) Imaging the adrenal medulla with an I-131-labeled anti-adrenergic agent. J Nucl Med 20:155–158

    PubMed  CAS  Google Scholar 

  12. Wieland DM, Brown LE, Rogers WL, Worthington KC, Wu JL, Clinthorne NH, Otto CA, Swanson DP, Beierwaltes WH (1981) Myocardial imaging with a radioiodinated storage analog. J Nucl Med 22:22–31

    PubMed  CAS  Google Scholar 

  13. Wieland DM, Mangner TJ, Inbasekaran MN, Brown LE, Wu J-L (1984) Adrenal medulla imaging agents: a structure distribution relationship study of radiolabeled aralkylguanidines. J Med Chem 27:149–155

    Article  PubMed  CAS  Google Scholar 

  14. Wieland DM, Wu JL, Brown LE, Mangner TJ, Swanson DP, Beierwaltes WH (1980) Radiolabeled adrenergic neuron blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med 21:349–353

    PubMed  CAS  Google Scholar 

  15. Wieland DM, Brown LE, Tobes MC, Rogers WL, Marsh DD, Mangner TJ, Swanson DP, Beierwaltes WH (1981) Imaging the primate adrenal medulla with [123I]and [131I] metaiodobenzylguanidine. J Nucl Med 22:358–364

    PubMed  CAS  Google Scholar 

  16. Sisson JC, Frager MS, Valk TW, Gross MD, Swanson DP, Wieland DM, Tobes MC, Beierwaltes WH, Thompson NW (1981) Scintigraphic localization of pheochromocytoma. N Engl J Med 305:12–17

    Article  PubMed  CAS  Google Scholar 

  17. Gasnier B, Roisin MP, Scherman D, Coornaert S, Desplanches G, Henry JP (1986) Uptake of meta-iodobenzylguanidine by bovine chromaffin granule membranes. Mol Pharmacol 29:275–280

    PubMed  CAS  Google Scholar 

  18. Guilloteau D, Baulieu J-L, Huguet F, Viel C, Chambon C, Valat C, Baulieu F, Itti R, Pourcelot L, Narcise G, Besnard J-C (1984) Meta-iodobenzylguanidine adrenal medulla localization: autoradiographic and pharmaceutical studies. Eur J Nucl Med 9:278–281

    Article  PubMed  CAS  Google Scholar 

  19. Jaques S Jr, Tobes MC, Sisson JC, Baker JA, Wieland DM (1984) Comparison of the sodium dependence of uptake of meta-iodobenzylguanidine and norepinephrine into cultured bovine adrenomedullary cells. Mol Pharmacol 26:539–546

    PubMed  CAS  Google Scholar 

  20. Shapiro B, Sisson JC, Kalff V, Glowniak J, Satterlee W, Glazer G, Francis IR, Bowers R, Thompson NW, Orringer M (1984) The location of middle mediastinal pheochromocytoma. J Thorac Cardiovasc Surg 87:814–820

    CAS  Google Scholar 

  21. Tobes MC, Jaques S, Wieland DM, Sisson JC (1985) Effect of uptake-one-inhibitors on the uptake of norepinephrine and meta-iodobenzylguanidine. J Nucl Med 26:897–907

    PubMed  CAS  Google Scholar 

  22. Kline RC, Swanson DP, Wieland DM, Thrall JH, Gross MD, Pitt B, Beierwaltes WH (1981) Myocardial imaging in man with I-123-meta-iodobenzylguanidine. J Nucl Med 22:129–132

    PubMed  CAS  Google Scholar 

  23. Feldman JM, Frankel N, Coleman RE (1984) Platelet uptake of the pheochromocytoma scanning agent 131I metaiodobenzylguanidine. Metabolism 33:397–399

    Article  PubMed  CAS  Google Scholar 

  24. Tobes MC, Fig LM, Carey L, Geatti O, Sisson JC, Shapiro B (1989) Alterations of iodine-131-MIBG biodistribution in an anephric patient: Comparisons to normal and impaired renal function. J Nucl Med 30:1476–1482

    PubMed  CAS  Google Scholar 

  25. Geatti O, Shapiro B, Shulkin B, Hutchinson RJ, Sisson JC (1988) Gastrointestinal iodine-131-meta-iodobenzylguanidine activity. Am J Physiol Imaging 3:189–191

    Google Scholar 

  26. Mangner TJ, Tobes MC, Wieland DM, Sisson JC, Shapiro B, Beierwaltes WH (1986) Metabolism of meta-I-131iodobenzylguanidine in patients with metastatic pheochromocytoma: concise communication. J Nucl Med 27:37–44

    PubMed  CAS  Google Scholar 

  27. Nakajo M, Shapiro B, Copp J, Kalif V, Gross MD, Sisson JC, Beierwaltes WH (1983) The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodobenzylguanidine (I-131-MIBG) in man: evaluation by scintigraphy. J Nucl Med 24:672–682

    PubMed  CAS  Google Scholar 

  28. Parisi MT, Sandler EP, Hattner RS (1992) The biodistribution of meta-iodobenzylguanidine. Semin Nod Med 22: 46–48

    Article  CAS  Google Scholar 

  29. Sisson JC, Lynch JJ, Johnson J, Jaques S, Wu D, Bolgos G, Lucchesi BR, Wieland DM (1988) Scintigraphic detection of regional disruption of adrenergic neurons in the heart. Am Heart J 116:67–76

    CAS  Google Scholar 

  30. Lynn MD, Shapiro B, Sisson JC, Swanson DP, Mangner TJ, Wieland DM, Meyers LJ, Glowniak JV, Beierwaltes WH (1984) Portrayal of pheochromocytoma and normal human adrenal medulla by I-123-meta-iodobenzylguanidine: concise communication. J Nucl Med 25:436–440

    PubMed  CAS  Google Scholar 

  31. Lynn MD, Shapiro B, Sisson JC, Beierwaltes WH, Meyers LJ, Ackermann R, Mangner TJ (1985) Pheochromocytoma and normal adrenal medulla: improved visualization with I-123MIBG scintigraphy. Radiology 156:789–792

    Google Scholar 

  32. Shulkin B, Shen S-W, Sisson JC, Shapiro B, Hutchinson R, Beierwaltes WH (1987) Normal and abnormal 131I-metaiodobenzylguanidine scintigraphy of the extremities. J Nucl Med 28:315–318

    PubMed  CAS  Google Scholar 

  33. Bomanji J, Moyes J, Huneidi AHS, Solanki K, Hawkins L, Nimmon CC, Kingston JE, Britton KE (1991) Cerebral uptake of MIBG: adrenoceptors visualized? Nucl Med Commun 12:3–13

    Article  PubMed  CAS  Google Scholar 

  34. Bomanji J, Flatman WD, Horne T, Fettich J, Britton KE, Ross G, Besser GM (1987) Quantitation of iodine-123 MIBG uptake by normal adrenal medulla in hypertensive patients. J Nucl Med 28:319–324

    PubMed  CAS  Google Scholar 

  35. Gross MD, Shapiro B (1989) Adrenal hypertension. Semin Nucl Med 19:122–143

    Article  PubMed  CAS  Google Scholar 

  36. Shapiro B, Gross MD (1987) Radiochemistry, biochemistry and kinetics of 131I-MIBG and 1231-MIBG: clinical implications of the use of 123I-MIBG. Med Pediatr Oncol 15:170–177

    Article  PubMed  CAS  Google Scholar 

  37. Petry NA, Shapiro B (1989) Radiopharmaceuticals for the endocrine system: adrenomedullary imaging. In: Swanson D, Chilton H, Thrall JH (eds) Pharmaceuticals in medical imaging. Macmillan, New York, pp 368–393

    Google Scholar 

  38. Swanson DP, Carey JE, Brown LE, Kline RC, Wieland DM, Thrall JH, Beierwaltes WH (1981) Human absorbed dose calculations for iodine-131 and iodine-123 labeled MIBG: a potential myocardial and adrenal medulla imaging agent. In: Proceedings of the Third International Radiopharmaceutical Dosimetry Symposium. (Health and Human Services Publications) FDA, Rockville, MD, pp 213–224

    Google Scholar 

  39. Corbett RP, Peacock J, Metter ST (1991) Inhibition of I-125 meta-iodobenzylguanidine (MIBG) uptake into neuroblastoma monolayers by antiemetic agents. Eur J Nucl Med 18:678

    Google Scholar 

  40. Khafagi FA, Shapiro B, Fig LM, Mallette S, Sisson JC (1989) Labetalol reduces iodine-131-MIBG uptake by pheochromocytoma and normal tissues. J Nucl Med 30:481–489

    PubMed  CAS  Google Scholar 

  41. Shapiro B, Wieland DM, Brown LE, Nakajo M, Sisson JC, Beierwaltes WH (1984c) 1311-meta-iodobenzylguanidine (MIBG) adrenal medullary scintigraphy: interventional studies. In: Spencer RP (ed) Interventional nuclear medicine. Grune & Stratton, New York, pp 451–481

    Google Scholar 

  42. Khafagi FA, Shapiro B, Gross MD(1991) The adrenal gland. In: Maisey MN, Britton KE, Gilday DL (eds) Clinical nuclear medicine, 2nd edn. Chapman & Hall Medical, London, pp 271–291

    Google Scholar 

  43. Slosman DO, Morel DR, Costabella PMM, Donath A (1988) Lung uptake of 131I-meta-iodobenzylguanidine in sheep: an in vivo measurement of pulmonary metabolic function. Eur J Nucl Med 14:65–70

    PubMed  CAS  Google Scholar 

  44. Shapiro B, Sisson JC (1988) Sympatho-adrenal imaging with radioiodinated meta-iodobenzylguanidine. In: Van Nostrand D, Baum S (eds) Atlas of nuclear medicine. Lippincott, Philadelphia, pp 72–114

    Google Scholar 

  45. Lindberg S, Fjalling M, Jacobsson L, Jansson Tisell L-E (1988) Methodology and dosimetry in adrenal medullary imaging with iodine-131-MIBG. J Nucl Med 29:1638–1643

    PubMed  CAS  Google Scholar 

  46. Shulkin B, Sisson JC, Koral KF, Shapiro B, Wang XH, Johnson J (1988) Conjugate view gamma camera method for estimating tumour uptake of iodine-131 meta-iodobenzylguanidine. J Nucl Med 29:542–548

    PubMed  CAS  Google Scholar 

  47. Hoefnagel CA, Klumper A, Voute PA (1987) Single photon emission tomography using I-131 meta-iodo-benzylguanidine in malignant pheochromocytoma and neuroblastoma. Case reports. J Med Imaging 1:57–60

    Google Scholar 

  48. Shapiro B, Sisson JC, Lloyd R, Nakajo M, Satterlee W, Beierwaltes WH (1984) Malignant pheochromocytoma: clinical, biochemical, and scintigraphic characterization. Clin Endocrinol (Oxf) 20:189–203

    Article  CAS  Google Scholar 

  49. Alavi A, Engelman K, Dweck E (1990) Perivesicle pheochromocytoma: the role of iodine-131-MIBG imaging. J Nucl Med 32:1669–1674

    Google Scholar 

  50. Francis IR, Glazer G, Shapiro B, Sisson JC, Gross BH (1983) Complementary roles of CT scanning and 131I-MIBG scintigraphy in the diagnosis of pheochromocytoma. Am J Ro entgen of 141:719–725

    CAS  Google Scholar 

  51. Endo K, Saga T, Koizumi M, Nakai T, Kawamura Y, Watanabe Y, Okazawa H (1989) Occult lung metastasis of pheochromocytoma detected by iodine-131-MIBG scintigraphy (abstract). J Nucl Med 30:885

    Google Scholar 

  52. Maurea S, Cuocolo A, Reynolds JC (1993) Iodine-131metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: comparison with CT and MRI. J Nucl Med 34:173–179

    PubMed  CAS  Google Scholar 

  53. Ackery DM, Tippett PA, Condon BR, Sutton HE, Wyeth P (1984) New approach to the localization of phaeochromocytoma: imaging with iodine-131-meta-iodobenzylguanidine. Br Med J 188:1587–1591

    Article  Google Scholar 

  54. Hanson MW, Feldman JM, Beam CA, Leight GS, Coleman RE (1992) Iodine-131-labeled meta-iodobenzylguanidine scintigraphy and biochemical analyses in suspected pheochromocytoma. Arch Intern Med 151:1397–1402

    Article  Google Scholar 

  55. Troncone L, Rufini V, Montemaggi P, Danza FM, Lasorella A, Mastrangelo R (1990) The diagnosis and therapeutic utility of radioiodinated meta-iodobenzylguanidine (MIBG). Five years’ experience. Eur J Nucl Med 16:325–335

    Article  PubMed  CAS  Google Scholar 

  56. Stein PP, Black HR (1991) A simplified diagnostic approach to pheochromocytoma: a review of the literature and report of one institution’s experience. Medicine 70:46–66

    Article  PubMed  CAS  Google Scholar 

  57. Warren MJ, Shapstone BJ, Soper N (1989) Iodine-131 metaiodobenzylguanidine (131I-MIBG) for the localization of suspected pheochromocytoma. Nucl Med Commun 10:467–475

    Article  PubMed  CAS  Google Scholar 

  58. Velchik MG, Alavi A, Kressel HY, Engelman K (1989) Localization of pheochromocytoma: MIBG, CT, and MRI correlation. J Nucl Med 30:328–336

    PubMed  CAS  Google Scholar 

  59. Mahlstedt J, Hotze A, Pichl J, Wolf (1984) Ergebnisse szintigraphischer Untersuchungen mit 131-I-meta-Benzylguanidin (MIBG) bei Raumforderungen neuroektodermaler Herkunft. Nucl Med 23:257–264

    CAS  Google Scholar 

  60. Koizumi M, Endo K, Sakahara H, Nakashima T, Nakano Y, Nakao K, Torizuka K (1986) Computed tomography and 131í-MIBG scintigraphy in the diagnosis of pheochromocytoma. Radiol Diagn 27:305–309

    CAS  Google Scholar 

  61. Swensen SJ, Brown ML, Sheps SG, Sizemore GW, Gharib H, Grant CS, Heerden JA van (1985) Use of 131I-MIBG scintigraphy in the evolution of suspected pheochromocytoma. Mayo Clin Proc 60:299–304

    PubMed  CAS  Google Scholar 

  62. Chatal JF, Charbonnel B (1985) Comparison of iodobenzylguanidine imaging with computed tomography in locating pheochromocytoma. J Clin Endocrinol Metab 61:769–772

    Article  PubMed  CAS  Google Scholar 

  63. Fischer M, Vetter W, Winterberg B, Hengstmann J, Zidek W, Friemann J, Vetter H (1984) Scintigraphic localization of pheochromocytomas. Clin Endocrinol 20:1–7

    Article  CAS  Google Scholar 

  64. Baulieu JL, Guilloteau D, Chambon C, Viel C, Baulieu F, Itti R, Pourcelot L, Besnard JC (1984) Meta-iodobenzylguanidine (MIBG) scintigraphy: a one year experience (abstract). J Nucl Med 25:111

    Google Scholar 

  65. Quint LE, Glazer GM, Francis IR, Shapiro B, Chenevert TL (1987) Pheochromocytoma and paraganglioma: comparison of MR imaging with CT and I-131-MIBG scintigraphy. Radiology 165:89–93

    PubMed  CAS  Google Scholar 

  66. Young MJ, Dmuchowski C, Wallis J, Barnas GP, Shapiro B (1989) Biochemical tests for pheochromocytoma: strategies in hypertensive patients. J Gen Intern Med 4:273–276

    Article  PubMed  CAS  Google Scholar 

  67. Berthold F (1990) Overview: biology of neuroblastoma. In: Pochedly C (ed) Neuroblastoma: tumor biology and therapy. CRC Press, Boca Raton, Fla., pp 2–27

    Google Scholar 

  68. Treuner J, Feine U, Niethammer D, Muller-Schauenburg W, Meinke J, Elbach E, Dopfer R, Klingebiel T, Grumback S (1984) Scintigraphic imaging of neuroblastoma with [131I]iodobenzylguanidine. Lancet 8372:333–334

    Article  Google Scholar 

  69. Geatti O, Shapiro B, Sisson JC, Hutchinson RJ, Mallette S, Eyre P, Beierwaltes WH (1985) Iodine-131 metaiodobenzylguanidine scintigraphy for the location of neuroblastoma: preliminary experience in ten cases. J Nucl Med 26:736–742

    PubMed  CAS  Google Scholar 

  70. Smets LA, Loesberg C, Janssen M, Metwally EA, Huiskamp R (1989) Active uptake and extravesicular storage of miodobenzylguanidine in human neuroblastoma SK-N-SH cells. Cancer Res 49:2941–2944

    PubMed  CAS  Google Scholar 

  71. Smets LA, Janssen M, Metwally E, Loesberg C (1990) Extra-granular storage of the neuron blocking agent metaiodobenzylguanidine (MIBG) in human neuroblastoma cells. Biochem Pharmacol 39:1959–1964

    Article  PubMed  CAS  Google Scholar 

  72. Suc A, Lumbroso J, Rubie H, Hattchouel JM, Boneu A, Rodary C, Robert A, Hartmann O (1996) Metastatic neuroblastoma in children older than one year: prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system. Cancer 77:805–811

    Article  PubMed  CAS  Google Scholar 

  73. Turba E, Fagioli G, Mancini AF, Rosito P, Galli A, Alvisi P (1993) Evaluation of stage 4 neuroblastoma patients by means of MIBG and 99mTc-MDP scintigraphy. J Nucl Biol Med 37:107–114

    PubMed  CAS  Google Scholar 

  74. Englaro EE, Gelfand MJ, Harris RE, Smith HS (1992) I-131 MIBG imaging after bone marrow transplantation for neuroblastoma. Radiology 182:515–520

    PubMed  CAS  Google Scholar 

  75. Lumbroso JD, Guermazi F, Hartmann O, Coornaert S, Rabarison Y, Leclere JG, Couanet D, Bayle C, Caillaud JM, Lemerle J (1988) Meta-iodobenzylguanidine (mIBG) scans in neuroblastoma: sensitivity and specificity, a review of 115 scans. Prog Clin Biol Res 271:689–705

    PubMed  CAS  Google Scholar 

  76. Feine U, Muller-Schauenburg W, Treuner J, Klingebiel T (1987) Metaiodobenzylguanidine (MIBG) labeled with 123I/ 1311 in neuroblastoma diagnosis and follow-up treatment with a review of the diagnostic results of the International Workshop of Pediatric Oncology held in Rome, September 1986. Med Pediatr Oncol 15:181–187

    Article  PubMed  CAS  Google Scholar 

  77. Heyman S, Evans AE, D’Angio GJ (1988) I-131 metaiodobenzylguanidine: diagnostic use in neuroblastoma patients in relapse. Med Pediatr Oncol 16:337–340

    Article  PubMed  CAS  Google Scholar 

  78. Schmiegelow K, Simes MA, Agertoft L, Berglund G, StormMathisen I, Andreassen M, Salmi TT, Nygard R, Wiebe T, Kreuger A (1989) Radio-iodobenzylguanidine scintigraphy of neuroblastoma: conflicting results, when compared with standard investigations. Med Pediatr Oncol 17:127–130

    Article  PubMed  CAS  Google Scholar 

  79. Troncone L, Rufini V, Danza FM, Donfrancesco A, De Laurentis C, Cozza R, Riccardi R, Lasorella A, Mastrangelo R (1990) Radioiodinated metaiodobenzylguanidine (*I-MIBG) scintigraphy in neuroblastoma: a review of 160 studies. J Nucl Med Allied Sci 34):279–288

    CAS  Google Scholar 

  80. Garty I, Friedman A, Sandler MP, Kedar A (1989) Neuroblastoma: Imaging evaluation by sequential Tc-99m-MDP, I-131MIBG and Ga-67 citrate studies. Clin Nucl Med 14:515–521

    Article  PubMed  CAS  Google Scholar 

  81. Yeh SDJ, Larson SM, Burch L, Kushner BH, Laqualia M, Finn R, Cheung N-KV (1991) Radioimmunodetection of neuroblastoma with iodine-131–3F8: correlation with biopsy, iodine-131-meta-iodobenzylguandine and standard diagnostic modalities. J Nucl Med 32:769–776

    PubMed  CAS  Google Scholar 

  82. Edeling C-J, Frederiksen PB, Kamper J, Jeppesen P (1987) Diagnosis and treatment of neuroblastoma using metaiodobenzylguanidine. Clin Nucl Med 8:632–637

    Article  Google Scholar 

  83. Claudiani F, Garaventa A, Scopingro G (1988) Diagnostic and therapeutic use of 131-I-metaiodobenzylguanidine in children with neuroblastoma. J Nucl Med Allied Sci 32:1–6

    PubMed  CAS  Google Scholar 

  84. Heyman S, Evans AE (1986) I-131-meta-iodobenzylguanidine (I-131-MIBG) in the diagnosis of neuroblastoma (abstract). J Nucl Med 27:931

    Google Scholar 

  85. Hadley GP, Rabe E (1986) Scanning with iodine-131-MIBG in children with solid tumors: an initial appraisal. J Nucl Med 27:620–626

    PubMed  CAS  Google Scholar 

  86. Harris RE, Gelfand MJ (1986) Sensitivity and utility of the 131-I-MIBG scan in childhood neuroblastoma. Proc Am Soc Clin Oncol 5:825

    Google Scholar 

  87. Munker T (1986) Scintigraphy of neuroblastoma. Nuklearmedizin Supp1:436–438

    Google Scholar 

  88. Fischer M, Galanski M, Winterberg B, Vetter H (1985) Localization procedures in pheochromocytoma and neuroblastoma. Cardiology 72 [Suppl 11:143–146

    Article  Google Scholar 

  89. Feine U, Treuner J, Niethammer D (1984) Erste Untersuchungen zur scintigraphischen Darstellung von Neuro-blastomen mit 131-J-meta-benzyl-quanidine. Nucl Compact 15:23–26

    Google Scholar 

  90. Shulkin BL, Shapiro B (1990) Radioiodinated MIBG in the management of neuroblastoma. In: Pochedly C (ed) Neuroblastoma tumor biology and therapy. CRC Press, Boca Raton, Fla., pp 171–198

    Google Scholar 

  91. Gelfand MJ (1996) I-123-MIBG and I-131-MIBG imaging in children with neuroblastoma. J Nucl Med 37:35P

    Google Scholar 

  92. Simon A, Hoefnagel CA, deKraker J (1992) 123IMIBG or 1311 MIBG for imaging of neuroblastoma. Eur J Nucl Med 19:589

    Google Scholar 

  93. Ruffini V, Fisher GA, Shulkin BL, Sisson JC, Shapiro B (1996) 123I-MIBG imaging of neuroblastoma: utility of SPECT and delayed imaging. J Nucl Med 37:1464–1468

    Google Scholar 

  94. Gelfand MJ, Elgazzar AH, Kriss VM, Masters P, Golsch GJ (1994) Iodine-123-MIBG SPECT versus planar imaging in children with neural crest tumors. J Nucl Med 35:1753–1757

    PubMed  CAS  Google Scholar 

  95. Giammarile F, Lumbroso J, Ricard M, Aubert B, Hartmann O, Schlumberger M, Parmentier C (1995) Radioiodinated metaiodobenzylguanidine in neuroblastoma: influence of high dose on tumour site detection. Eur J Nucl Med 22:1180–1183

    Article  PubMed  CAS  Google Scholar 

  96. Leung A, Shapiro B, Hattner R (1997) The specificity of radioiodinated MIBG for neural crest tumors in childhood. J Nucl Med 38:1352–1357

    CAS  Google Scholar 

  97. Khafagi F, Shapiro B, Fischer M (1991) Pheochromocytomas and functioning paraganglioma in childhood and adolescence: role of iodine 131 metaiodobenzylguandine. Eur J Nucl Med 18:191–198

    Article  PubMed  CAS  Google Scholar 

  98. Shulkin BL, Shapiro B, Hutchinson RJ (1992) Iodine-131metaiodobenzylguanidine and bone scintigraphy for the detection of neuroblastoma. J Nucl Med 33:1735–1740

    PubMed  CAS  Google Scholar 

  99. Gordon I, Peters AM, Gutman A, Morony S, Dicks-Mireaux C, Pritchard J (1990) Skeletal assessment in neuroblastoma - the pitfalls of iodine-123-MIBG scans. J Nucl Med 31:129–134

    PubMed  CAS  Google Scholar 

  100. Hadj-Djilani NL, Lebtahi NE, Delaloye AB, Laurini R, Beck D (1995) Diagnosis and follow-up of neuroblastoma by means of iodine-123 metaiodobenzylguanidine scintigraphy and bone scan, and the influence of histology. Eur J Nucl Med 22:322–329

    Article  PubMed  CAS  Google Scholar 

  101. Osmanagaoglu K, Lippens M, Benoit Y, Obrie E, Schelstraete K, Simons M (1993) A comparison of iodine-123 metaiodobenzylguanidine scintigraphy and single bone marrow aspiration biopsy in the diagnosis and follow-up of 26 children with neuroblastoma. Eur J Nucl Med 20:1154–1160

    Article  PubMed  CAS  Google Scholar 

  102. Corbett R, Olliff J, Fairley N, Moyes J, Husband J, Pinkerton R, Carter R, Treleaven J, McElwain T, Meller S (1991) A prospective comparison between magnetic resonance imaging, meta-iodobenzylguanidine scintigraphy and marrow histologycytology in neuroblastoma. Eur J Cancer 27:1560–1564

    Article  PubMed  CAS  Google Scholar 

  103. Shulkin B, Shapiro B, Tobes M, Shen S-W, Wieland D, Meyers L, Lee H, Petry N, Sisson J, Beierwaltes W (1986) 123I-4Amino-3-iodobenzylguanidine (123I-AIBG), a new sympathoadrenal imaging agent: comparison with 123I-metaiodobenzylguanidine (123 I-MIBG). J Nucl Med 27:1138–1142

    PubMed  CAS  Google Scholar 

  104. Shulkin BL, Wieland DM, Baro ME, Ungar DR, Mitchell DS, Dole MG, Rawwas JB, Castle VP, Sisson JC, Hutchinson RJ (1996) PET hydroxyephedrine imaging of neuroblastoma. J Nucl Med 37:16–21

    PubMed  CAS  Google Scholar 

  105. Shulkin BL, Wieland DM, Shapiro B, Sisson JC (1995) PET Epinephrine studies of pheochromocytoma. J Nucl Med 36:22P–23P

    Google Scholar 

  106. Vaidynathan G, Sffleck DJ, Zalutsky MR (1994) 4-[18F]Fluoro-3-iodobenzylguanidine, a potential MIBG analogue for positron emission tomography. J Med Chem 37:3655–3662

    Article  Google Scholar 

  107. Vaidyanathan G, Strickland DK, Zalutsky MR (1994) Meta- [211 At] astatobenzylguanidine: further evaluation of a potential therapeutic agent. Int J Cancer 57:908–913

    Article  PubMed  CAS  Google Scholar 

  108. Melvin KEV (1986) Medullary carcinoma of the thyroid. In: Ingbar SH, Braverman LE (eds) Werner’s the thyroid. Lippincott, Philadelphia, pp 1349–1362

    Google Scholar 

  109. Troncone L, Rufini V (1992) Medullary thyroid cancer: new trends in diagnosis and therapy. In: Carpi A, Sagripanti A, Mittermayer CH (eds) Progress in clinical oncology. Sympomed, München, pp 227–250

    Google Scholar 

  110. Poston GJ, Thomas AMK, McDonald WR (1986) Imaging of metastatic medullary carcinoma of the thyroid with 131-Imetaiodobenzylguanidine. Nucl Med Commun 7:215–221

    Article  PubMed  CAS  Google Scholar 

  111. Hilditch TE, Connell JMC, Elliott AT (1986) Poor results with technetium-99 m(V)DMSA and iodine-131-MIBG in the imaging of medullary thyroid carcinoma. J Nucl Med 27:1150–1153

    PubMed  CAS  Google Scholar 

  112. Baulieu JL, Guilloteau D, Delisle MJ (1987) Radioiodinated meta-iodobenzylguanidine uptake in medullary thyroid cancer. A French cooperative study. Cancer 60:2189–2194

    Article  PubMed  CAS  Google Scholar 

  113. Clarke SEM, Lazarus CR, Wraight P (1988) Pentavalent 99mTc-DMSA, 131-I-MIBG, and 99mTc-MDP. An evaluation of three imaging techniques with medullary carcinoma of the thyroid. J Nucl Med 29:33–38

    PubMed  CAS  Google Scholar 

  114. Hoefnagel CA, Delprat CC, Zanin D, Van der Schoot JB (1988) New radionuclide tracers for the diagnosis and therapy of medullary thyroid carcinoma. Clin Nucl Med 13:159–165

    Article  PubMed  CAS  Google Scholar 

  115. Guerra UP, Pizzocaro L, Terzi A (1989) New tracers for the imaging of the medullary thyroid carcinoma. Nucl Med Commun 5:285–295

    Article  Google Scholar 

  116. Valk TW, Frager MS, Gross MD, Sisson JC, Wieland DM, Swanson DP, Mangner TJ, Beierwaltes WH (1981) Spectrum of pheochromocytma in multiple endocrine neoplasia. Ann Intern Med 94:762–767

    PubMed  CAS  Google Scholar 

  117. Clarke SEM, Lazarus CR, Wraight P, Sampson C, Maisey MN (1988) Pentavalent 99m-Tc DMSA, 131í-MIBG and 99m-Tc MDP-an evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid. J Nucl Med 29:33–38

    PubMed  CAS  Google Scholar 

  118. Hoefnagel CA, Den Hartog Jager FCA, Taal BG, Abeling NGGM, Engelsman EE (1989) The role of 131-I-MIBG in the diagnosis and therapy of carcinoids; and Addendum. In: The clinical use of 131-I-metaiodobenzylguanidine for the diagnosis and treatment of neural crest tumours. Academisch proefschrift. Koninklijke drukkerij, Callenbach, Nijkerk, The Netherlands, pp 117–130

    Google Scholar 

  119. Sinzinger H, Renner F, Granegger S (1985) 131-I-MIBG imaging of carcinoids and apudomas. Eur J Nucl Med 11:A17

    Article  Google Scholar 

  120. Feldman JM, Blinder RA, Lucas KJ, Coleman RE (1986) Iodine-131-metaiodobenzylguanidine scintigraphy of carcinoid tumors. J Nucl Med 27:1691–1696

    PubMed  CAS  Google Scholar 

  121. McEwan AJ, Catz Z, Field S (1987) I-131-metaiodobenzylguanidine (mIBG) in the diagnosis and treatment of carcinoid syndrome. J Nucl Med 28:658

    Google Scholar 

  122. Jodrell DJ, Irvine AT, McCready VR, Woodcraft E, Smith IE (1988) The use of 131-I-MIBG in the imaging of metastatic carcinoid tumors. Br J Cancer 58:663–664

    Article  PubMed  CAS  Google Scholar 

  123. Castellani MR, Di Bartolomeo M, Maffoli L, Zilembo N, Gasparini M, Buraggi GL (1991) 131-I-MIBG therapy in carcinoid tumors. J Nucl Biol Med 35:349–351

    PubMed  CAS  Google Scholar 

  124. Caballero O, Ferris J, Verdeguer A, Esquembre C, Castel V (1986) Visualization of ganglioneuroma by means of scintigraphy with 131-I-MIBG. Eur J Nucl Med 12:351–352

    Article  PubMed  CAS  Google Scholar 

  125. Bomanji J, Kingston JE, Hungerford JL, Britton KE (1989) 123-I-meta-iodobenzylguandine scintigraphy of ectopic intracranial retinoblastoma. Med Pediatr Oncol 17:66–68

    Article  PubMed  CAS  Google Scholar 

  126. Geatti O, Shapiro B, Barillari B (1989) Scintigraphic depiction of an insulinoma by I-131-metaiodobenzylguanidine. Clin Nucl Med 14:903–906

    Article  PubMed  CAS  Google Scholar 

  127. Somers G, Houte KV, Segers O, Bossuyt A (1988) Iodine-123MIBG imaging in a generalized pancreatic polypeptidegastrinserotonin secreting tumor. Clin Nucl Med 13:352–355

    Article  PubMed  CAS  Google Scholar 

  128. Lamberts SWJ, Krenning EP, Reubi J-C (1991) The role of somatostatin and its analogs in the diagnosis and treatment of tumours. Endocr Rev 12:450–482

    Article  PubMed  CAS  Google Scholar 

  129. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WAP, Kooij PPM, Oei HY, VanHagen M, Postema PTE, Jong M de, Reubi JL, Visser TJ, Regis AEM, Hofland LJ, Koper JW, Lamberts SWJ (1993) Somatostatin receptor scintigraphy with E111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Ratterdam experience with more than 1000 patients. Eur J Nucl Med 20:716–731

    Article  PubMed  CAS  Google Scholar 

  130. Bakker WH, Alberts R, Bruns C, Breeman WAP, Hofland LJ, Marbach P, Pless J, Pralet D, Stolz B, Koper JW, Lamberts SWJ, Visser TJ, Krenning EP (1991) [111-In-DPTA-D-PHE1]Octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumours: synthesis, radiolabelling and in vitro validation. Life Sci 49:1583–1591

    Article  PubMed  CAS  Google Scholar 

  131. Krenning EP, Bakker WH, Breeman WAP, Koper JW, Kooij PPM, Ausema L, Lameris JS, Lamberts SWJ (1989) Localization of endocrine related tumours with radioiodinated analogue of somatostatin. Lancet I:242–245

    Article  Google Scholar 

  132. Lamberts SWJ, Hofland LJ, Koetsveld PM van, Reubi JC, Bruining HA, Bakker WH, Krenning EP (1990) Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumours. Consequences with regard to diagnosis, localisation and therapy. J Clin Endocrinol Metab 71:566–574

    Article  PubMed  CAS  Google Scholar 

  133. Lamberts SWJ, Bakker WH, Reubi JC, Krenning EP (1990) Somatostatin receptor imaging in the localization of endocrine tumours. N Engl J Med 323:1246–1249

    Article  PubMed  CAS  Google Scholar 

  134. Krenning EP, Bakker WH, Kooij PPM, Breeman WAP, Oei HY, Jong M de, Reubi J-C, Visser TJ, Bruns C, Kwekkeboom DJ, Reijs AEM, Hagen PM van, Koper JW, Lamberts SWJ (1992) Somatostatin receptor scintigraphy with [111-InDTPA-D-PHE1]-octreotide in man: metabolism, dosimetry and comparison with [123-I-Tyr-3-]-octreotide. J Nucl Med 33:652–658

    PubMed  CAS  Google Scholar 

  135. Bakker WH, Krenning EP, Breeman WA, Koper JW, Kooy PPM, Reubi JC, Klijn JGM, Viser TJ, Docter R, Lamberts SWJ (1990) Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabelling, purification, biological activity and in vivo applications in animals. J Nucl Med 31:1501–1509

    PubMed  CAS  Google Scholar 

  136. Kwekkeboom DJ, Krenning EP, Bakker WH, Oei HY, Splinter TAW, Kho GS, Lamberts SWJ (1991) Radioiodinated somatostatin analog scintigraphy in small-cell lung cancer. J Nucl Med 32:1845–1848

    PubMed  CAS  Google Scholar 

  137. Kwekkeboom DJ, Hoff AM, Lamberts SWJ, Oei HY, Krenning EP (1992) Somatostatin analogue scintigraphy: a simple and sensitive method for the in vivo visualization of Merkel cell tumours and their metastases. Arch Dermatol 128:818–821

    Article  PubMed  CAS  Google Scholar 

  138. Krenning EP, Kwekkeboom DJ, Oei HY, Reubi JC, Hagen PM van, Kooij PPM, Reijs AEM, Lamberts SWJ (1992) Somatostatin receptor imaging of endocrine gastrointestinal tumours. Schweiz Med Wochenschr 122:634–637

    PubMed  CAS  Google Scholar 

  139. Bestagno M, Pizzocaro C, Maira G, Terzi A, Panarotto MB, Guerra P (1991) Results of [131I]metaiodobenzylguanidine treatment in metastatic malignant phaeochromocytoma. J Nucl Biol Med 35:277–279

    CAS  Google Scholar 

  140. Colombo L, Lomuscio G, Vignati A, Dottorini ME (1991) Preliminary results of [131I]metaiodobenzylguanidine treatment in metastatic malignant pheochromocytoma. J Nucl Biol Med 35:300–304

    PubMed  CAS  Google Scholar 

  141. Fischer M (1991) Therapy of pheochromocytoma with [l31I]metaiodobenzylguanidine. J Nucl Biol Med 35:292–294

    PubMed  CAS  Google Scholar 

  142. Hoefnagel CA, Schornagel J, Valdes O.RA (1991) [131I]Metaiodobenzylguanidine therapy of malignant pheochromocytoma: interference of medication. J Nucl Biol Med 35:308–312

    PubMed  CAS  Google Scholar 

  143. Krempf M, Lumbroso J, Mornex R, Brendel AJ, Wemeau JL, Delisle MJ, Aubert B, Carpentier P, Fleury-Goyen MC, Gibold C, Guyot M, Lahneche B, Marchandise X, Schlumberger M, Charbonnel B, Chatal JF (1991) Treatment of malignant pheochromocytoma with [131I]metaiodobenzylguanidine. A French multicenter study. J Nucl Biol Med 35:284–287

    PubMed  CAS  Google Scholar 

  144. Lewington VJ, Zivanovic MA, Tristam M, McEwan AJB, Ackery DM (1991) Radiolabelled metaiodobenzylguanidine targeted radiotherapy for malignant phaeochromocytoma. J Nucl Biol Med 35:280–283

    PubMed  CAS  Google Scholar 

  145. Schwartz C, Delisle M-J (1991) Results of [1311]metaiodobenzylguanidine therapy administrated to two patients with medullary carcinoma of the thyroid. J Nucl Biol Med 35:332–333

    Google Scholar 

  146. Shapiro B, Sisson JC, Wieland DM, Mangner TJ, Zempel SM, Mudgett E, Gross MD, Carey JE, Zasadny KR, Beierwaltes WH (1991) Radiopharmaceutical therapy of malignant pheochromocytoma with [131 I]metaiodobenzylguanidine: results from ten years of experience. J Nucl Biol Med 35:269–276

    PubMed  CAS  Google Scholar 

  147. Troncone L, Rufini V, Daidone MS, De Santis M, Luzi S (1991) [131I]Metaiodobenzylguanidine treatment of malignant pheochromocytoma: experience of the Rome group. J Nucl Biol Med 35:295–299

    PubMed  CAS  Google Scholar 

  148. Sisson JC, Shapiro B (1995) Neural crest structures: treatment. In: Wagner HN, Szabo Z, Buchanan JW (eds) Principles of nuclear medicine, 2nd edn. Saunders, Philadelphia, pp 680–686

    Google Scholar 

  149. Castellani MR, Rottoli L, Maffioli L, Massimino M, Gasparini M, Buraggi GL (1991) Experience with pallitative [131I]metaiodobenzylguanidine therapy in advanced neuroblastoma. J Nucl Biol Med 35:241–243

    PubMed  CAS  Google Scholar 

  150. Claudiani F, Garaventa A, Bertolazzi L, Villavecchia GP, Cabria M, Scopinaro G, Bestagno M, Guerra P, Canevarollo N, Scielzo G, Lanino E, De Bernardi B (1991) [131I]Metaiodobenzylguanidine therapy in advanced neuroblastoma. J Nucl Biol Med 35:224–227

    CAS  Google Scholar 

  151. Hoefnagel CA, Voute PA, De Kraker J, Valdes O.RA (1991) [131I]Metaiodobenzylguanidine therapy after conventional therapy for neuroblastoma. J Nucl Biol Med 35:202–206

    PubMed  CAS  Google Scholar 

  152. Hör G, Maul FD, Kornhuber B, Schwabe D, Hesse J, Mane-gold KH, Baüm RP, Gerein V (1991) Outcome of [131 I]metaiodobenzylguanidine therapy of neuroblastoma: seven years after. J Nucl Biol Med 35:207–215

    PubMed  Google Scholar 

  153. Hutchinson RJ, Sisson JC, Miser JS, Zasadny KR, Normolle DP, Shulkin BL, Francis IR, Wieland DM, Shapiro B (1991) Long-term results of [131I]metaiodobenzylguanidine treatment of refractory advanced neuroblastoma. J Nucl Biol Med 35:237–240

    PubMed  CAS  Google Scholar 

  154. Klingebiel T, Feine U, Treuner J, Reuland P, Handgretinger R, Niethammer D (1991) Treatment of neuroblastoma with [131I]metaiodobenzylguanidine: long-term results in 25 patients. J Nucl Biol Med 35:216–219

    PubMed  CAS  Google Scholar 

  155. Lumbroso J, Hartmann O, Schlumberger M (1991) Therapeutic use of [131I]metaiodobenzylguanidine in neuroblastoma: a phase II study in 26 patients. J Nucl Biol Med 35:220–223

    PubMed  CAS  Google Scholar 

  156. Matthay KK, Huberty JP, Hattner RS, Ablin AR, Engelstad BL, Zoger S, Hasegawa BH, Price D (1991) Efficacy and safety of [131I] metaiodobenzylguanidine therapy for patients with refractory neuroblastoma. J Nucl Biol Med 35:244–247

    PubMed  CAS  Google Scholar 

  157. Troncone L, Rufini V, Riccardi R, Lasorella A, Mastrangelo R (1991) The use of [131I]metaiodobenzylguanidine in the treatment of neuroblastoma after conventional therapy. J Nucl Biol Med 35:232–236

    CAS  Google Scholar 

  158. Bernard BF, Krenning EP, Breeman WAP, Kolleman EJ, Bakker WH, Visser TJ, Mäeke, J. M de (1997) D-Lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med 38:1929–1933

    PubMed  CAS  Google Scholar 

  159. Shapiro B (1991) Summary, conclusions, and future directions of 131-I-metaiodobenzylguanidine therapy in the treatment of neural crest tumors. J Nucl Biol Med 35:357–363

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. B. Shapiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. M. Fig
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. D. Gross
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. L. Shulkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. C. Sisson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. School of Medicine, Kocaeli University, Kocaeli, Turkey

    Cumali Aktolun MD, MSc

  2. Medical Center, University of Pittsburgh, 200 Lothrop Street, Pittsburgh, PA, 15213, USA

    W. Newlon Tauxe MD

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Shapiro, B., Fig, L.M., Gross, M.D., Shulkin, B.L., Sisson, J.C. (1999). Neuroendocrine Tumors. In: Aktolun, C., Tauxe, W.N. (eds) Nuclear Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-58643-9_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-58643-9_1

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-63680-6

  • Online ISBN: 978-3-642-58643-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation